FLXN Flexion Therapeutics Inc.

14.15
+0.34  (+2%)
Previous Close 13.81
Open 13.78
Price To Book 12.98
Market Cap 539,208,970
Shares 38,106,641
Volume 466,390
Short Ratio
Av. Daily Volume 624,163
Stock charts supplied by TradingView

NewsSee all news

  1. Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®

    BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company it needs additional time to

  2. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 80,550 stock options and 13,425

  3. Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA)

    BURLINGTON, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics (NASDAQ:FLXN) is teaming up with Chris Dickerson, a former New York Yankees outfielder and member of the 2011 and 2012 playoff teams, to raise

  4. Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

    BURLINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual Cell

  5. Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.

    Interactive memorial developed by the National Safety Council pays tribute to more than 22,000 victims of the opioid crisis and offers resources to help stem the epidemicExhibit will be on display Sept. 23-28 at the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 enrolment paused due to non-safety issue - May 8, 2019. Set to recommence 4Q 2019.
Zilretta
Osteoarthritis of the hip
Approval announced October 6, 2017.
Zilretta - FX006
Osteoarthritis of the knee
Phase 2 top-line data released November 2016.
Zilretta - FX006
Osteoarthritis of the knee with type 2 adult diabetes
PDUFA date for sNDA filing delayed by around a couple weeks from original date of October 14, 2019. No exact date provided.
Zilretta - FX006 repeat
Osteoarthritis of the knee
Top-line safety data due 2Q 2018.
Zilretta - FX006
Osteoarthritis of the knee
Clinical trials to commence 2H 2019 following IND filing.
FX201
Osteoarthritis (OA)

Latest News

  1. Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®

    BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company it needs additional time to

  2. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 80,550 stock options and 13,425

  3. Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA)

    BURLINGTON, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics (NASDAQ:FLXN) is teaming up with Chris Dickerson, a former New York Yankees outfielder and member of the 2011 and 2012 playoff teams, to raise

  4. Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

    BURLINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual Cell

  5. Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.

    Interactive memorial developed by the National Safety Council pays tribute to more than 22,000 victims of the opioid crisis and offers resources to help stem the epidemicExhibit will be on display Sept. 23-28 at the

  6. Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

    Flexion's new locally delivered product candidate, FX301, will combine Xenon's NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogelFX301 is a potential first-in-class therapy with the aim of providing pain

  7. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to nine new employees consisting of an aggregate of 25,900 stock options and 4,350

  8. Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference

    BURLINGTON, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led